Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Crystal Pharmatech Launches OEB4/OEB5 High-Potency Laboratory, Expanding Global CDMO Capabilities for Complex Drug Development

April 28, 2026 at 12:00 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

New Suzhou facility complements existing U.S. infrastructure, delivering dual-continent containment capabilities for high-potency API programs

SUZHOU, China - April 28, 2026 - PRLog -- Crystal Pharmatech, a global leader in solid-state and formulation science, today announced the official launch of its new OEB4/OEB5 high-potency laboratory at its headquarters in Suzhou, China. The facility has successfully passed rigorous third-party exposure control testing and is now fully operational.

The state-of-the-art laboratory features full-room negative pressure containment, dedicated gowning areas, an independent exhaust system, and five high-performance isolators compliant with ISPE standards and JG/T385:2012. It is equipped with advanced instrumentation including XRPD, TGA, DSC, and high-precision analytical balances to support safe solid-state research and crystallization under containment.

This new Suzhou facility complements Crystal Pharmatech's existing OEB4/OEB5 capabilities at its U.S. site in Cranbury, New Jersey, creating seamless dual-continent support for highly potent APIs (HPAPIs), including oncology and targeted small-molecule therapies.

Clients can now access integrated early-stage services such as Mol2Med™ Developability Assessment, polymorph screening, solid-state characterization, single crystal structure determination, preformulation, and small-scale crystallization process development (≤20 g) in a fully contained environment.

The expansion strengthens Crystal Pharmatech's position as a trusted global CDMO partner, helping biotech companies reduce development risks, accelerate timelines, ensure operator safety, and advance complex drug programs with confidence.

About Crystal Pharmatech

Crystal Pharmatech provides end-to-end solid-state and formulation solutions from preclinical to clinical stages, with operations in China, the United States, and Canada.

Contact
Crystal Pharmatech Co., Ltd.
***@crystalpharmatech.com

Photos: (Click photo to enlarge)